FRIDAY DEADLINE: Berger Montague Advises Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026
Telix Pharmaceuticals Limited - American Depositary Shares (TLX)
Company Research
Source: GlobeNewswire
PHILADELPHIA, Jan. 07, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) (“Telix” or the “Company”) on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the “Class Period”). Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Telix, headquartered in Melbourne, Australia, is a biopharmaceutical company specializing in radiopharmaceutical development for cancer treatment. Defendants allegedly made false or misleading statements and/or failed to disclose that: (1) progress on prostate cancer therapeutic candidates had been materially overstated; (2) the quality and performance of the Company’s supply chain and partners had been
Show less
Read more
Impact Snapshot
Event Time:
TLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLX alerts
High impacting Telix Pharmaceuticals Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TLX
News
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis StudyPR Newswire
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis StudyGlobeNewswire
- Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLXGlobeNewswire
- TLX FINAL DEADLINE ALERT: Hagens Berman Alerts Telix Pharm. (TLX) Investors of Today’s Lead Plaintiff Deadline in Securities Class ActionGlobeNewswire
- TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their RightsGlobeNewswire
TLX
Sec Filings
- 1/12/26 - Form 6-K
- 12/22/25 - Form 6-K
- 12/17/25 - Form 6-K
- TLX's page on the SEC website